TLK1 and cancer: Although the short TLK1 isoform phosphorylates many of the same target proteins as the full-length in vitro [59], the altered ratio of isoforms in cancer cells warrants investigation into the preferred substrates of isoform 3 in vivo that contribute to resistance to genotoxic chemotherapeutics and radiation.